About: Vanucizumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer. Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche.

Property	Value
dbo:abstract	Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer. Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. (en)
dbo:casNumber	1448221-05-3
dbo:fdaUniiCode	B800Z06O8K
dbo:kegg	D11244
dbo:wikiPageID	50977046 (xsd:integer)
dbo:wikiPageLength	2267 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	981994160 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Angiopoietin-2 dbr:Bevacizumab dbr:Hoffmann-La_Roche dbr:Genentech dbr:Monoclonal_antibody dbc:Experimental_cancer_drugs dbr:International_Nonproprietary_Name dbc:Monoclonal_antibodies dbr:Humanized dbr:Angiopoietin_2 dbr:VEGF-A
dbp:atcPrefix	none (en)
dbp:c	6529 (xsd:integer)
dbp:casNumber	1448221 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	10033 (xsd:integer)
dbp:kegg	D11244 (en)
dbp:mabType	mab (en)
dbp:n	1733 (xsd:integer)
dbp:o	2038 (xsd:integer)
dbp:s	46 (xsd:integer)
dbp:source	zu (en)
dbp:synonyms	RG7221 (en)
dbp:target	dbr:Angiopoietin_2
dbp:type	mab (en)
dbp:unii	B800Z06O8K (en)
dbp:wikiPageUsesTemplate	dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Drugbox dbt:Monoclonal-antibody-stub dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Experimental_cancer_drugs dbc:Monoclonal_antibodies
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer. Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. (en)
rdfs:label	Vanucizumab (en)
owl:sameAs	yago-res:Vanucizumab wikidata:Vanucizumab https://global.dbpedia.org/id/2PQ3y
prov:wasDerivedFrom	wikipedia-en:Vanucizumab?oldid=981994160&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Vanucizumab
is dbo:wikiPageWikiLink of	dbr:List_of_therapeutic_monoclonal_antibodies
is foaf:primaryTopic of	wikipedia-en:Vanucizumab